UnitedHealth and Johnson & Johnson Raise Full-Year Guidance Following Q3 Earnings

UnitedHealth Group Incorporated (UNH) and Johnson & Johnson (JNJ) both raised their full-year financial outlooks after publishing third-quarter financial results. UnitedHealth delivered adjusted earnings per share of $4.69 on revenue of $112.69 billion, beating market expectations as its medical cost ratio improved to 88.4 percent. Meanwhile, Johnson & Johnson recorded adjusted earnings per share of $2.59 on $25.4 billion in revenue, driven by pharmaceutical sales despite softness in its medical technology segment.

The reports highlight contrasting operating trends across the healthcare sector. UnitedHealth benefitted from tighter medical cost management, allowing executive leadership to boost its full-year earnings target to at least $20.50 per share, well above consensus targets. Conversely, Johnson & Johnson raised its annual earnings forecast to between $11.05 and $11.15 per share, though its target fell slightly short of Wall Street estimates as cardiovascular and surgical equipment sales missed projections.

Investors will monitor whether UnitedHealth can maintain cost controls while navigating reimbursement pressure in its Medicare Advantage plans and ongoing headwinds at its Optum division. For Johnson & Johnson, attention will center on whether pharmaceutical momentum can offset slower growth in medical devices and support its multi-decade dividend growth record.